85 related articles for article (PubMed ID: 17360185)
1. Inflammatory breast cancers in Tunisia and France show similar immunophenotypes.
Charafe-Jauffret E; Mrad K; Intidhar Labidi S; Ben Hamida A; Ben Romdhane K; Ben Abdallah M; Ginestier C; Esterni B; Birnbaum D; Ben Ayed F; Xerri L; Viens P; Mezlini A; Jacquemier J
Breast; 2007 Aug; 16(4):352-8. PubMed ID: 17360185
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
3. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
McCarthy NJ; Yang X; Linnoila IR; Merino MJ; Hewitt SM; Parr AL; Paik S; Steinberg SM; Hartmann DP; Mourali N; Levine PH; Swain SM
Clin Cancer Res; 2002 Dec; 8(12):3857-62. PubMed ID: 12473600
[TBL] [Abstract][Full Text] [Related]
4. Persistent E-cadherin expression in inflammatory breast cancer.
Kleer CG; van Golen KL; Braun T; Merajver SD
Mod Pathol; 2001 May; 14(5):458-64. PubMed ID: 11353057
[TBL] [Abstract][Full Text] [Related]
5. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.
Faratian D; Munro A; Twelves C; Bartlett JM
Histopathology; 2009 Jan; 54(2):254-7. PubMed ID: 19207951
[TBL] [Abstract][Full Text] [Related]
6. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
7. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
[TBL] [Abstract][Full Text] [Related]
8. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin.
Ben Hamida A; Labidi IS; Mrad K; Charafe-Jauffret E; Ben Arab S; Esterni B; Xerri L; Viens P; Bertucci F; Birnbaum D; Jacquemier J
BMC Cancer; 2008 Jan; 8():28. PubMed ID: 18230143
[TBL] [Abstract][Full Text] [Related]
9. Tissue microarray validation: a methodologic study with special reference to lung cancer.
Karlsson C; Bodin L; Piehl-Aulin K; Karlsson MG
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2014-21. PubMed ID: 19531681
[TBL] [Abstract][Full Text] [Related]
10. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
11. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
12. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
13. BP1, a putative signature marker for inflammatory breast cancer and tumor aggressiveness.
Man YG; Schwartz A; Levine PH; Teal C; Berg PE
Cancer Biomark; 2009; 5(1):9-17. PubMed ID: 19242057
[TBL] [Abstract][Full Text] [Related]
14. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.
Nguyen DM; Sam K; Tsimelzon A; Li X; Wong H; Mohsin S; Clark GM; Hilsenbeck SG; Elledge RM; Allred DC; O'Connell P; Chang JC
Clin Cancer Res; 2006 Sep; 12(17):5047-54. PubMed ID: 16951220
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?
Anderson WF; Chu KC; Chang S
J Clin Oncol; 2003 Jun; 21(12):2254-9. PubMed ID: 12805323
[TBL] [Abstract][Full Text] [Related]
16. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
17. Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients.
Lê MG; Arriagada R; Contesso G; Cammoun M; Pfeiffer F; Tabbane F; Bahi J; Dilaj M; Spielmann M; Travagli JP; Tursz T; Mourali N
Clin Breast Cancer; 2005 Dec; 6(5):439-45. PubMed ID: 16381628
[TBL] [Abstract][Full Text] [Related]
18. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
19. Characterization of columnar cell lesions of the breast: immunophenotypic analysis of columnar alteration of lobules with prominent apical snouts and secretions.
Dessauvagie BF; Zhao W; Heel-Miller KA; Harvey J; Bentel JM
Hum Pathol; 2007 Feb; 38(2):284-92. PubMed ID: 17084437
[TBL] [Abstract][Full Text] [Related]
20. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
